Home » Newsletters » BioWorld Science

BioWorld Science

March 20, 1998

View Archived Issues

Shire: Interim Report 1997

PD-72953 raises HDL by activating a peroxisomal receptor?

Company Profile: Sheffield Pharmaceuticals

QLT and Ciba Vision initiate phase IIIb verteporfin trial

Ebselen therapy more cost-effective than standard therapy

Progenics' HIV products show promise in phase I/II clinical trials

Mochida describes PDE V inhibitors for pulmonary hypertension, ischemic heart disease

Compounds modulating apolipoprotein production in development at Nisshin Flour Milling

Antiplatelet agents reported by researchers at Nippon Steel

Lilly reveals new series of hypoglycemic/hypolipidemic compounds

New antineoplastic glutamic acid derivatives synthesized at Princeton

Selective functional AMPA antagonists patented by ADIR

Botox effective in controlling focal hyperhidrosis

Flamel Technologies: Q4 and year-end 1997 highlights

Approval recommended for Gemzar supplemental NDA

T-20 + efavirenz + protease inhibitors to be evaluated in HIV patients

Vitamin C prevents development of nitrate tolerance in CHF

Schering-Plough and Chugai sign marketing agreement for psoriasis drug

Patient enrollment completed for phase III studies of pramlintide

Fluoxetine for premature ejaculation

Polyether from marine sponge possesses both antitumor and antifungal properties

Daiichi to market Nycomed Amersham's ultrasound contrast agent in Japan

CEA-Scan to be distributed by Bergen Brunswig in U.S.

U. of Alberta researchers discover novel 1,4-dihydropyridine calcium channel modulators

Introgen granted option for tumor suppressor gene

Progress made in Lilly/Emisphere protein delivery collaboration

Popular Stories

NIH changes set industry up for workforce, ideas drought
BioWorld
On March 1, 2025, former NIH director Francis Collins’ announced that he had fully resigned from the NIH, where he continued to lead a laboratory after his...
Today's news in brief
BioWorld
BioWorld briefs for March 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for March 12, 2025
At CROI, HIV cure trials raise hopes for broader applicability
BioWorld
At the 2025 meeting of the Conference on Retroviruses and Opportunistic Infections (CROI) it was the best of times, it was the worst of times. On the first full...
Hummingbird migrates ADCs, tech to newco Callio’s $187M debut
BioWorld
Antibody-drug conjugate (ADC)-focused Callio Therapeutics debuted on March 3 with the closing of a $187 million series A financing round based on cancer drug...